Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window After rejecting ...

Please provide your email address to receive an email when new articles are posted on . Being diagnosed with thyroid cancer and hypoparathyroidism may raise risk for several comorbidities. Targeted ...

Ascendis Pharma has obtained US Food and Drug Administration (FDA) approval for its YORVIPATH (palopegteriparatide) to treat hypoparathyroidism in adults. Hypoparathyroidism is a rare endocrine ...

Results showed eneboparatide compared with placebo met the primary endpoint with statistical significance at 24 weeks. Topline data were announced from a phase 3 trial evaluating eneboparatide in ...

(BPT) – This June, the HypoPARAthyroidism Association, Inc. (HPA) is intent on making its mark within the rare disease community. In honor of World Hypoparathyroidism Awareness Day, an annual global ...

Please provide your email address to receive an email when new articles are posted on . Most adults with hypoparathyroidism had normalized calcium levels without needing a supplement after 3 months of ...

Older people treated for Graves disease with total thyroidectomy in the United States are at low risk of developing hypoparathyroidism, according to results from a large population-based cohort study.

Only about 10 cases of hypoparathyroidism related to systemic lupus erythematosus (SLE) have been reported, according to researchers who recently described such a case. Hypoparathyroidism associated ...

Pharmascience unit Pendopharm has entered an exclusive distribution agreement with Ascendis Pharma to bring the hypoparathyroidism treatment TransCon PTH (palopegteriparatide) to the Canadian market.

Patients with chronic hypoparathyroidism faced a significantly higher risk for cardiovascular diseases and mortality from cardiovascular causes than control individuals without the condition, with the ...